M
MorphoSys
Biotechnology company focused on the research and development of fully human antibodies
At a glance
- Status
- Listed
- Listing
- IPO 2018
News
Open roles
MorphoSys in the Planegg ecosystem
The MorphoSys office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A4 investors entered at this stage
- GEGenentech
Third Rock Ventures- TGThe Column Group
Venrock
Series B and later4 investors entered at this stage
- MSMax Planck Society
- MIMax Planck Innovation
- MIMax Planck Institute for Biological Intelligence
- MBMax Planck Institute of Biochemistry
Source: Dealroom Talent Intelligence.
Patents
152 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where MorphoSys was the backer or acquirer, 2010–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
4 deals across MorphoSys's capital deployment.
Where the deals concentrate by sector, stage, and decade.
MorphoSys's portfolio, mapped.
See MorphoSys on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


